Overall rank by patents
#39,080
Across all tracked assignees
USPTO 2015–2025 USPTO PatentsView Foreign Corporation
Biophytis
USPTO PatentsView assignee record - 6 granted patents across 11 technology areas, active 2018–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS).
6
Total patents granted
11
CPC technology areas
13.8
Avg claims per patent
-50%
5-year filing velocity
The verdict
Biophytis holds 6 US patents across 11 technology areas, rank #39,080 of 50,000 tracked assignees.
- #39,080
- of 50,000 US assignees by volume
- Top 71%
- by Innovation Score (29.0/100)
- 13.8
- avg claims per patent
- -50%
- filing velocity, last 5 yrs
Portfolio overview
Biophytis has been granted 6 US utility patents between 2018 and 2025, placing Biophytis at rank #39,080 across all assignees tracked by PlainPatent. This portfolio spans 11 distinct Cooperative Patent Classification (CPC) subclasses, averaging 13.8 claims per patent with primary concentration in A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS). As a Foreign Corporation, Biophytis is one of the more focused assignees in the PatentsView dataset. By volume, Biophytis sits between Bioiberica, S.a.u. (6 patents, rank #39,076) and Biosynth S.r.l. (6 patents, rank #39,084) - the closest US assignees by grant volume. The composite Innovation Score of 29.0/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 2 grants, compared with 4 in the 2015–2019 window, a -50% shift in five-year velocity. A cooling filing rate may reflect portfolio consolidation, shifting priorities, or reduced R&D throughput. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Biophytis's 13.8 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while concentration in 11 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Biophytis against peers pursuing similar technology classes.
Who files at Biophytis's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- Bioiberica U
BIOIBERICA, S.A.U.
6 patents
- Biomerenewables
BIOMERENEWABLES INC.
6 patents
- Biondan North Ame…
BIONDAN NORTH AMERICA INC.
6 patents
- Biopetrolia AB
BIOPETROLIA AB
6 patents
- Bioretec OY
BIORETEC OY
6 patents
- BIOS
BIOS Co., Ltd
6 patents
- Biospan
BIOSPAN TECHNOLOGIES, INC.
6 patents
- Biosynth S R L
BIOSYNTH S.R.L.
6 patents
- Biophytis ◀
BIOPHYTIS
6 patents
What this shows Biophytis holds 6 patents at rank #39,080, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near Biophytis
By rank, the assignees closest to #39,080 in granted patent volume.
- Bioiberica, S.a.u. #39,076 · 6 patents
- Biomerenewables Inc. #39,077 · 6 patents
- Biondan North America Inc. #39,078 · 6 patents
- Biopetrolia AB #39,079 · 6 patents
- Bioretec OY #39,081 · 6 patents
- BIOS Co., Ltd #39,082 · 6 patents
- Biospan Technologies, Inc. #39,083 · 6 patents
- Biosynth S.r.l. #39,084 · 6 patents
Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)
Other assignees with the most granted patents in Biophytis's primary technology class.
- The Regents Of The University Of California 1,387 in class
- Novartis Ag 1,071 in class
- Merck Sharp & Dohme Llc 889 in class
- Bristol-myers Squibb Company 879 in class
- Genentech, Inc. 789 in class
- The Board Of Regents Of The University Of Texas System 744 in class
- Hoffmann-la Roche Inc. 722 in class
- The United States Of America, As Represented By The Secretary, Department Of Health And Human Services 721 in class
Biophytis's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
29 Top 71% higher than 29% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2018–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2018 | 1 | 16.7% |
| 2019 | 3 | 50.0% |
| 2023 | 1 | 16.7% |
| 2025 | 1 | 16.7% |
Which technologies does Biophytis patent most?
Top 11 of 11 technology areas
Patent Moat Analysis
Portfolio Volume Light
Tech Breadth Focused
Claim Depth Standard
Velocity Declining
Frequently Asked Questions
How many patents does Biophytis hold?
Biophytis holds 6 US granted patents filed between 2018 and 2025, spanning 11 technology areas.
What is Biophytis's Innovation Score?
Biophytis has an Innovation Score of 29.0 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Biophytis focus on?
Biophytis's top technology area is A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS) with 6 patents. The company has filed patents in 11 CPC subclasses total.
Is Biophytis's patent filing rate increasing or decreasing?
Biophytis's recent filing velocity is -50% compared to the prior five-year period. Filing activity has slowed relative to earlier years.
What does claim depth mean for Biophytis's patents?
Biophytis's patents average 13.8 claims each. This falls within the standard range, providing solid legal coverage.
How is the Biophytis patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.
How to use this portfolio
Biophytis's 6 grants land it in the top 71% by Innovation Score, but volume alone doesn't tell you where the strength sits.
- Read that count against the largest US assignees before treating it as dominance - Biophytis ranks #39,080 of 50,000. Top 50 holders
- Most of this portfolio concentrates in A61P - see who else leads that technology area. A61P leaders
- Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.